Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Pharm Res. 2016 Jul 11;33(10):2530–2539. doi: 10.1007/s11095-016-1977-2

Figure 4. Tumor retention, biodistribution and pharmacokinetics of B-381 in vivo.

Figure 4

Tumor boron concentration analyzed by ICP-OES after intratumoral injection of left tumor with BPA (23.3 mg/kg mouse, equivalent to 0.02 mmol boron/mouse) and intratumoral injection of right tumor with B-381 (42.9 mg/kg mouse, equivalent to 0.02 mmol boron/mouse) (A). Biodistribution of boron 24 h after intravenous injection of 100 mg/kg B-381 into D54 glioma bearing mice, sacrificed 24 h post-injection and boron content determined by ICP-OES (B). Pharmacokinetic analysis of boron blood levels after intravenous injection of 50 mg/kg of B-381 using naïve mice analyzed by ICP-OES (C).